Uncategorized

Acadia Healthcare looks ugly on the surface, which is exactly why I think it is becoming interesting. The stock is beaten down, earnings are distorted by massive special charges, litigation concerns remain a real overhang, leverage is not insignificant, and investor trust has clearly been damaged. This is not a clean compounder story. It is […]

For most of the past several years, Novo Nordisk represented one of the clearest “can’t lose” stories in global healthcare investing. Obesity drugs were exploding in popularity, Ozempic became a cultural phenomenon, Wegovy transformed the medical discussion around weight loss, and investors began treating Novo as though it had effectively secured a near-monopolistic position in

There are certain investments that retail investors look at and immediately dismiss because they seem painfully unexciting. iShares 1-5 Year Investment Grade Corporate Bond ETF is one of those investments. At first glance, it almost looks like the financial equivalent of oatmeal. No revolutionary AI story.No crypto narrative.No moonshot upside.No billionaire founder promising to “change

Tilman Fertitta’s reported effort to acquire Caesars Entertainment is being discussed publicly as a casino merger, but that framing actually understates what the transaction really represents. This is not simply one gaming operator buying another. It is an attempt to assemble one of the largest vertically integrated hospitality and consumer-entertainment ecosystems in the United States

Banco Santander’s proposed acquisition of Webster Financial is the kind of transaction that exposes the strange contradiction at the center of modern banking regulation. For years, regulators encouraged banks to become safer, better capitalized, more diversified, and more resilient to liquidity shocks. But once banks attempt to achieve exactly those goals through consolidation, regulators simultaneously

Texas Instruments’ proposed acquisition of Silicon Labs is not the kind of semiconductor merger regulators can casually wave through anymore. Ten years ago, this probably would have been viewed primarily as an industrial efficiency transaction: one highly capable semiconductor company acquiring another complementary technology platform in order to deepen product offerings, improve manufacturing economics, and

JBS is one of those companies the market consistently struggles to value correctly because investors still tend to frame it through an outdated lens. Many people continue thinking about JBS as a cyclical Brazilian meatpacker exposed primarily to cattle prices and commodity swings. That description may have been directionally accurate twenty years ago, but it

ARGT is one of the strangest and most fascinating ETFs in the market because it does not behave like a traditional country fund. Most country ETFs are relatively straightforward macro products tied to broad economic growth, demographics, industrial activity, or commodity exposure. ARGT is different. It is fundamentally a credibility trade. The ETF is really

TV is the type of stock most investors stop looking at long before the opportunity potentially becomes interesting. The chart looks terrible, the sentiment surrounding legacy media is awful, earnings have been ugly for years, and the company operates in a part of the market most institutional investors increasingly avoid unless they absolutely need exposure

For years, investors viewed Boston Scientific as a solid but somewhat inconsistent medical device company — respected, diversified, operationally improved under CEO Michael Mahoney, but not necessarily considered part of the elite tier of healthcare compounders. That perception has changed dramatically over the last several years, and despite recent market volatility surrounding the stock, the